Ep 223 [08 July 2026]: Schiffon Wong MPH, Founder and Principal of Schiffon Wong Strategic Advisory, where she advises biopharma executive leaders on evidence strategy for market access. She brings over 20 years of healthcare and life sciences experience, including nearly two decades inside pharma evidence functions — most notably as VP and Head of Neurology & Immunology, Global Value Demonstration at EMD Serono, with earlier roles at Bristol-Myers Squibb and Deloitte. She holds an MPH in Epidemiology from Columbia University and has authored approximately 100 publications and presentations. We discussed Schiffon's unique background and discussed that policy changes today are forcing a step-change in evidence rigor, Schiffon will focus on what that pressure exposes organizationally, and why research methodology is now table stakes, not the differentiator it was in the past. JCA — Joint Clinical Assessment, the EU-level HTA (Health Technology Assessment) process that took effect in 2025, requiring coordinated clinical evidence evaluation across member states before national reimbursement decisions. MFN — Most Favored Nation, a U.S. drug pricing policy concept requiring manufacturers to match the lowest price paid by comparable countries, with implications for how value must be demonstrated domestically. IRA — Inflation Reduction Act, the 2022 U.S. legislation that introduced Medicare drug price negotiation, among other provisions, fundamentally reshaping how manufacturers think about evidence requirements earlier in development. Please check-out our website to join the club, get updates and see podcast recordings: https://rwd-rwe.club Disclaimer: The views expressed in this podcast are the guest's and host's alone, and do not reflect the official position of any organization or entity with whom they are, or have been, professionally affiliated.